Clinical Outcome of Palliative Surgery After Translational Therapy for Metastatic Gastric Cancer Versus Maintenance Chemotherapy for Metastatic Gastric Cancer

Inclusion Criteria

• •Age from 18 to 75 years
• •Primary gastric adenocarcinoma (papillary, tubular, mucinous, signet ring cell, or poorly differentiated) confirmed pathologically
• •CT/MRI, PET-CT, or laparoscopic exploration should be performed before surgery to confirm the diagnosis of distant metastasis
• •Performance status of 0 or 1 on Eastern Cooperative Oncology Group scale (ECOG)
• •Estimated survival time was over 3 months
• •The major organs are functioning normally and meet the following criteria:
• •(1) Blood routine examination should meet the requirements (no blood transfusion within 14 days):
• •1. HB≥100g/L，
• •2. WBC≥3×109/L
• •3. ANC≥1.5×109/L，
• •4. PLT≥100×109/L； （2）Biochemical tests must meet the following criteria：
• •<!-- -->
• •1. BIL \<1.5×upper limit of normal (ULN)，
• •2. ALT and AST\<2.5ULN，GPT≤1.5×ULN；
• •3. Cr≤1ULN，Ccr \>60ml/min
• •Fertile women must have taken a pregnancy test (serum) within 7 days prior to enrollment with negative results and be willing to use an appropriate method of contraception during the trial period and 8 weeks after the last trial drug; For men, they should be surgically sterilized or agree to use the appropriate method of contraception during the trial period and 8 weeks after the last administration of the trial drug
• •Did not participate in other clinical studies before and during treatment
• •Subjects voluntarily joined the study and signed informed consent with good compliance and follow-up